The Experts below are selected from a list of 132 Experts worldwide ranked by ideXlab platform
Joao Rocha - One of the best experts on this subject based on the ideXlab platform.
-
behavioral and neurochemical effects induced by Reserpine in mice
Psychopharmacology, 2016Co-Authors: Catiuscia Molz De Freitas, Joao Rocha, Alcindo Busanello, Larissa Finger Schaffer, Luis Ricardo Peroza, Barbara Nunes Krum, Caroline Queiroz Leal, Ana Paula Chiapinotto Ceretta, Roselei FachinettoAbstract:Reserpine, a monoamine-depleting agent, which irreversibly and non-selectively blocks the vesicular monoamine transporter, has been used as an animal model to study several neurological disorders, including tardive dyskinesia and Parkinson’s disease. The purpose of this study was to examine if motor deficits induced by Reserpine in mice could be related to alterations in the expression of dopaminergic system proteins such as tyrosine hydroxylase (TH) and dopamine transporter (DAT) and in the activity of monoamine oxidase (MAO). Mice received either vehicle or Reserpine (0.1, 0.5, or 1 mg/kg, s.c.) for four consecutive days. Two, 20, or 60 days after Reserpine withdrawal, behavioral, and neurochemical changes were evaluated. Reserpine at a dose of 0.5 and 1 mg/kg increased vacuous chewing movements (VCMs) and reduced locomotion. Behavioral changes were accompanied by reduction in TH immunoreactivity in the striatum evaluated on days 2 and 20 after the last injection of 1 mg/kg Reserpine. Furthermore, negative correlations were found between VCM and MAO-A or MAO-B on day 2 and TH striatal immunoreactivity on day 20 after the last injection of 1 mg/kg Reserpine. A positive correlation was observed between VCMs and DAT immunoreactivity in the substantia nigra on day 2 after the last injection of 0.5 mg/kg Reserpine. These findings suggest that the pharmacological blockage of vesicular monoamine transporter (VMAT) by Reserpine caused neurochemical and behavioral alterations in mice.
-
ebselen attenuates Reserpine induced orofacial dyskinesia and oxidative stress in rat striatum
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2003Co-Authors: Audrei De Oliveira Alves, Luciano Callegari, Fernanda R Athayde, Cristina W Nogueira, Gilson Zeni, Joao RochaAbstract:Reserpine-induced orofacial dyskinesia is an alleged animal model of tardive dyskinesia whose pathophysiology has been related to striatal oxidative stress. In the present investigation, the authors examined whether ebselen, an antioxidant organochalcogen with glutathione peroxidase-like activity, changes the behavioral and neurochemical effect of acute Reserpine administration. Reserpine injection for 3 days every other day caused a significant increase on the tongue protrusion frequency and ebselen (30 mg/kg ip for 4 days, starting 1 day before Reserpine) reversed partially the effect of Reserpine (P<.05). Reserpine- and Reserpine+ebselen-treated groups displayed an increase in vacuous chewing frequency when compared to control and ebselen-treated groups (P<.05) Reserpine increased the duration of facial twitching and ebselen reversed partially the effect of Reserpine (P<.01). Reserpine increased significantly the thiobarbituric acid-reactive species (TBARS) levels, and ebselen reversed the effect of Reserpine on TBARS production in rat striatum. The results of the present study clearly indicated that ebselen has a protective role against Reserpine-induced orofacial dyskinesia and reversed the increase in TBARS production caused by Reserpine administration. Consequently, the use of ebselen as a therapeutic agent for the treatment of tardive dyskinesia should be considered.
Zhao Yi-bing - One of the best experts on this subject based on the ideXlab platform.
-
Determination of Reserpine by in situ sensitized photochemical spectrofluorimetry
Analytica Chimica Acta, 1995Co-Authors: Xu Jin-gou, Chen Huiping, Guo Xiang-qun, Zhao Yi-bingAbstract:An in situ photochemical spectrofluorimetic method for the rapid and precise determination of Reserpine was proposed. Adding acetone to the Reserpine solution in acetic acid medium will speed up the photochemical conversion of Reserpine into an intensively fluorescent compound. The determination can be carried out by measuring the fluorescence intensity at a fixed time. The mechanism of the sensitization of acetone was also discussed. The linear concentration range of the calibration graphs was found to be 0-0.91 mu g ml(-1). The detection limit was 0.40 ng ml(-1) Reserpine and the relative standard deviation was 0.75% for 0.40 ng ml(-1) Reserpine (n = 6). The recovery for its application to Reserpine injections was 97.3-103%. Through a standard addition recovery test, we obtained a recovery between 91.3 and 100% in urine samples. Interference effects of some common ions in serum and foreign substances coexisting with Reserpine in complex Reserpine tablets were also tested
Pierre-marie Laduron - One of the best experts on this subject based on the ideXlab platform.
-
Axonal transport of dopamine-containing vesicles labelled in vivo with [3H]Reserpine
European Journal of Neuroscience, 1993Co-Authors: Delphine Lechardeur, M. N. Castel, M. Reibaud, D. Scherman, Pierre-marie LaduronAbstract:Axonal transport of the vesicular monoamine transporter was assayed in the rat brain by in vivo binding of the specific ligand [3H]Reserpine. Because of the marked localization of Reserpine binding sites in dopaminergic cell bodies and nerve terminals, the dopaminergic nigrostriatal pathway was chosen for the study of the axonal transport of the monoamine carrier present in the membrane of synaptic vesicles. When labelled Reserpine was injected into the substantia nigra, a delayed accumulation of radioactivity in the ipsilateral striatum was observed approximately 4 h after the injection. Similarly, injection into the right striatum was followed by a substantial accumulation of radioactivity in the ipsilateral substantia nigra, which was prevented by peripheral injection of unlabelled Reserpine or tetrabenazine. This process was rapid and dependent on microtubules. In senescent rats, the amount of retrogradely transported [3H]Reserpine was significantly reduced. These results demonstrate that labelled Reserpine may be used to monitor in vivo fast axonal transport in central neurons.
Audrei De Oliveira Alves - One of the best experts on this subject based on the ideXlab platform.
-
ebselen attenuates Reserpine induced orofacial dyskinesia and oxidative stress in rat striatum
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2003Co-Authors: Audrei De Oliveira Alves, Luciano Callegari, Fernanda R Athayde, Cristina W Nogueira, Gilson Zeni, Joao RochaAbstract:Reserpine-induced orofacial dyskinesia is an alleged animal model of tardive dyskinesia whose pathophysiology has been related to striatal oxidative stress. In the present investigation, the authors examined whether ebselen, an antioxidant organochalcogen with glutathione peroxidase-like activity, changes the behavioral and neurochemical effect of acute Reserpine administration. Reserpine injection for 3 days every other day caused a significant increase on the tongue protrusion frequency and ebselen (30 mg/kg ip for 4 days, starting 1 day before Reserpine) reversed partially the effect of Reserpine (P<.05). Reserpine- and Reserpine+ebselen-treated groups displayed an increase in vacuous chewing frequency when compared to control and ebselen-treated groups (P<.05) Reserpine increased the duration of facial twitching and ebselen reversed partially the effect of Reserpine (P<.01). Reserpine increased significantly the thiobarbituric acid-reactive species (TBARS) levels, and ebselen reversed the effect of Reserpine on TBARS production in rat striatum. The results of the present study clearly indicated that ebselen has a protective role against Reserpine-induced orofacial dyskinesia and reversed the increase in TBARS production caused by Reserpine administration. Consequently, the use of ebselen as a therapeutic agent for the treatment of tardive dyskinesia should be considered.
Shrinivas K Kulkarni - One of the best experts on this subject based on the ideXlab platform.
-
effect of withania somnifera root extract on Reserpine induced orofacial dyskinesia and cognitive dysfunction
Phytotherapy Research, 2006Co-Authors: Pattipati S Naidu, Amanpreet Singh, Shrinivas K KulkarniAbstract:Tardive dyskinesia is one of the major side effects of long-term neuroleptic treatment. The pathophysiology of this disabling and commonly irreversible movement disorder is still obscure. Vacuous chewing movements in rats are widely accepted as an animal model of tardive dyskinesia. Oxidative stress and products of lipid peroxidation are implicated in the pathophysiology of tardive dyskinesia. Repeated treatment with Reserpine (1.0 mg/kg) on alternate days for a period of 5 days (days 1, 3 and 5) signicantly induced vacuous chewing movements and tongue protrusions in rats. Chronic treatment with Withania somnifera root extract (Ws) for a period of 4 weeks to Reserpine treated animals signicantly and dose dependently (50 and 100 mg/kg) reduced the Reserpine-induced vacuous chewing movements and tongue protrusions. Reserpine treated animals also showed poor retention of memory in the elevated plus maze task paradigm. Chronic Ws administration signicantly reversed Reserpine-induced retention decits. Biochemical analysis revealed that chronic Reserpine treatment signicantly induced lipid peroxidation and decreased the glutathione (GSH) levels in the brains of rats. Chronic Reserpine treated rats showed decreased levels of antioxidant defense enzymes, superoxide dismutase (SOD) and catalase. Chronic administration of Ws root extract dose dependently (50 and 100 mg/kg) and signicantly reduced the lipid peroxidation and restored the decreased glutathione levels by chronic Reserpine treatment. It also signicantly reversed the Reserpine-induced decrease in brain SOD and catalase levels in rats. The major ndings of the present study indicate that oxidative stress might play an important role in the pathophysiology of Reserpine-induced abnormal oral movements. In conclusion, Withania somnifera root extract could be a useful drug for the treatment of drug-induced dyskinesia. Copyright © 2006 John Wiley & Sons, Ltd.
